대웅

003090KOSPI의약품 제조업

58.0 / 100

Reference Date: 2026-07-24

Financial Score27.5 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure12.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 1.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Woong Co., Ltd., a global healthcare group holding company, reported consolidated sales of 2.684 trillion KRW in 2025, a 6.8% increase from the previous year, though operating profit declined 7.1% to 2.618 billion KRW. Its subsidiary Dae Woong Pharm achieved 13.91 trillion KRW in sales and 2.036 billion KRW in operating profit in 2025, driven by growth in key products like Nabohta and Pexuclo, as well as investments in R&D and digital healthcare initiatives.

Number of Employees

413people

Average Salary

69.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

4.23Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR

0.55Industry Average 0.815.5Point

Lower than industry avg (good)

ROE

13.94Industry Average 4.017.0Point

3.5x industry avg (excellent)

Debt Ratio

39.33Industry Average 12.430.0Point

3.2x industry avg (risky)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.5% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 10.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 16,570Won52-week high 29,35052-week low 15,850

1-month return3.0Point

1m -1.25% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 1Neutral 1Negative 0

Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 국내 3상 임상시험계획(IND) 승인(미란성 위식도역류질환 치료 후 유지요법))2026-07-10
Positive단일판매ㆍ공급계약체결(자회사의 주요경영사항)2026-06-26